Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 160.18M | $ 194.62M | $ 292.60M | $ 213.58M | $ 295.31M |
| Gross Profit | $ 97.00M | $ 120.47M | $ 207.81M | $ 60.18M | $ -601.00K |
| Operating Income | $ -50.47M | $ -46.26M | $ -63.18M | $ -265.32M | $ -376.44M |
| EBITDA | $ -13.72M | $ -6.87M | $ -43.26M | $ -225.96M | $ -341.00M |
| Net Income | $ -69.41M | $ -51.92M | $ -106.01M | $ -244.87M | $ -349.87M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 51.87M | $ 42.92M | $ 90.47M | $ 149.80M | $ 268.69M |
| Total Assets | $ 220.67M | $ 241.70M | $ 351.83M | $ 525.55M | $ 644.14M |
| Total Debt | $ 3.55M | $ 104.18M | $ 99.78M | $ 136.05M | $ 126.28M |
| Net Debt | $ -48.32M | $ 61.26M | $ 9.32M | $ -13.75M | $ -102.41M |
| Total Liabilities | $ 269.86M | $ 272.29M | $ 342.49M | $ 449.09M | $ 396.52M |
| Stockholders' Equity | $ -49.19M | $ -30.58M | $ 9.34M | $ 76.46M | $ 247.62M |
| Cash Flow | |||||
| Free Cash Flow | $ -40.69M | $ -23.38M | $ -73.27M | $ -253.02M | $ -110.70M |
| Operating Cash Flow | $ -40.66M | $ -23.38M | $ -73.15M | $ -252.97M | $ -110.39M |
| Investing Cash Flow | $ -33.00K | $ 0.00 | $ -114.00K | $ 39.94M | $ -40.00M |
| Financing Cash Flow | $ 49.66M | $ -25.21M | $ 14.60M | $ 133.73M | $ 231.72M |